anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
African American and low-income populations bear a disproportionate burden of dementia and have been underrepresented in trials of cognitive impairment. The Systolic Blood Pressure Intervention Trial (SPRINT) showed that an intensive blood pressure (BP) intervention (target systolic BP \<120 mmHg) lowered the risk of cognitive impairment compared to a standard BP intervention (systolic BP target \<140 mmHg). The next important step is to determine how the successful SPRINT intensive blood pressure intervention can be implemented in a real-world clinic setting to prevent cognitive decline. The overall objective of the proposed study is to test a multifaceted strategy for implementing an intensive BP intervention protocol adapted from SPRINT targeting systolic BP \<120 mmHg on cognitive decline in racial minority and low-income hypertensive patients in resource-constrained primary care practices in Louisiana and Mississippi. The RE-AIM (Reach Effectiveness Adoption Implementation Maintenance) framework has been used to guide the development and evaluation of the multifaceted implementation strategy, including protocol-based treatment that employs the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT findings, shared- decision making, team-based collaborative care, BP audit and feedback, home BP monitoring, and patient health coaching. Building on the ongoing Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS-BP) trial, the investigators will cost-effectively conduct a cluster- randomized trial in 40 primary care clinics that serve low-income populations in Louisiana and Mississippi. The primary outcome in the proposed trial is the net difference in mean change of global cognitive composite z-score from baseline to an average of 36 months between the intervention and enhanced usual care groups. Secondary outcomes include net difference in mean change of executive function and memory composite z-scores, systolic and diastolic BP, adverse effects, and quality of life. Implementation outcomes, including acceptability, adaptation, adoption, feasibility, fidelity, penetrance, and cost-effectiveness, will also be collected and used to improve intervention delivery during the trial. The proposed trial, with a sample size of 40 clinics (31.5 patients/clinic), has 93% statistical power to detect a 0.30 or higher difference in the global cognitive composite z-score at a 2-sided significance level of 0.05 assuming 20% loss to follow-up and an intra-cluster correlation of 0.05. In a meta-analysis of 5 clinical trials, the pooled effect size was 0.35 (95% CI 0.32, 0.38) for the global cognitive composite z-score. This study will generate urgently needed data on effective, adoptable, and equitable intervention strategies to reduce blood pressure-related cognitive decline in low-income and minority populations. If proven effective, the implementation strategy for intensive blood pressure reduction could be adapted and scaled up in diverse primary care settings to prevent cognitive decline and clinical dementia.
During the intervention period, patients in the usual care arm will conduct self-monitored blood glucose (SMBG) at least 4 times/day. At Weeks 6 and 12 of the intervention period, usual care arm patients will also undergo 10-days of blinded CGM data collection.
INTRODUCTION: Radical surgery combined with chemotherapy is the only potential curative treatment of patients with advanced epithelial ovarian cancer (EOC). However, 43% of older Danish patients with EOC are not referred to surgery due to frailty, age, or fear of complications. Comprehensive geriatric assessment (CGA) has demonstrated ability to reduce frailty in older patients, but there is a knowledge gap regarding its effect before or during treatment in older adults with EOC. This protocol presents a randomized controlled trial (RCT), which evaluates the effect of CGA-based interventions including individualized physical exercise therapy in older adults with EOC during neoadjuvant chemotherapy (NACT).
MATERIALS AND METHODS: This RCT will include patients aged ≥70 years with primary EOC referred to NACT. Patients will be randomized 1:1 to intervention or standard of care, along with neoadjuvant antineoplastic treatment. Stratification for performance status and center of inclusion will be performed. In the intervention arm, a geriatrician will perform CGA and corresponding geriatric interventions and patients will undergo an individualized home-based exercise program managed by a physiotherapist. All patients will be evaluated with Geriatric-8, modified Geriatric-8, clinical frailty scale, and physical tests at randomization. Predictive values (positive/negative) will be evaluated for CGA detected impairments. The primary endpoint is the proportion of patients referred to interval debulking surgery (IDS). Secondary endpoints include the proportion who complete oncological treatment, improvements in physical tests, quality of life measured by European Organization for Research and Treatment of Cancer-Quality of Life questionnaires at inclusion, after three cycles of chemotherapy, and at end of chemotherapy treatment. Furthermore, the association between results of geriatric screening tests, CGA, and physical tests with complication rate and progression free survival will be examined. The primary outcome will be analyzed with logistic regression in the intention-to-treat population. Power calculations reveal the need to enroll 216 patients.
DISCUSSION: The present study examines whether CGA-based interventions including individualized physical exercise can increase the referral rate for potential curative IDS in older patients with EOC. If successful, this will result in more patients undergoing surgery and completing chemotherapy, preventing complications, and ultimately improving quality of life and survival. The study setup may establish the basis for direct clinical implementation if proven effective.
In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
BACKGROUND: Cancer-associated fibroblasts (CAFs) and hepatocellular carcinoma (HCC) cells interact to promote HCC progression, but the underlying mechanisms remain unclear. Serpin family E member 1 (SERPINE1) has conflicting roles in HCC, and microRNAs (miRNAs) are known to regulate tumor progression through intercellular communication. Therefore, we investigated the potential involvement of miRNA/SERPINE1 axis in crosstalk between CAFs and HCC cells.
METHODS: In this study, candidate miRNAs targeting SERPINE1 3' UTR were predicted using multiple miRNA databases. The miRNAs and SERPINE1 mRNA expression in Huh7 cells was assessed after co-culture with CAFs using RT-qPCR. Huh7 cell proliferation and invasion were detected after SERPINE1 siRNA. The functions of the CAF-derived miR-642a-3p/SERPINE1 axis in HCC cells were examined using CCK-8, wound healing, transwell assays, western blot, and dual-luciferase reporter assays. Moreover, a orthotopic xenograft model was used to investigate the contribution of miR-642a-3p knockdown in HCC.
RESULTS: SERPINE1 mRNA expression decreased, while miR-642a-3p expression increased in Huh7 cells co-cultured with CAFs. SERPINE1 knockdown enhanced Huh7 cell proliferation and invasion as well as miR-642a-3p expression. miR-642a-3p overexpression promoted migration, invasion, and epithelial-mesenchymal transition (EMT) in Huh7 cells by targeting SERPINE1, while miR-642a-3p knockdown yielded the opposite effect. Rescue experiments confirmed that SERPINE1 knockdown attenuated the inhibitory effects of miR-642a-3p knockdown on migration, invasion, and EMT in Huh7 cells. Importantly, miR-642a-3p knockdown suppressed growth and EMT in orthotopic liver tumors.
CONCLUSION: CAF-derived miR-642a-3p/SERPINE1 axis facilitated migration, invasion, and EMT in the HCC cells, suggesting miR-642a-3p/SERPINE1 axis can be a potential therapeutic target for HCC.
The invention discloses a novel application of the extract of Rheum emodi Wall., and more specifically discloses an application of the extract of Rheum emodi Wall. in preparing a medicine for preventing and treating IHD. According to results of animal experiments, the extract of Rheum emodi Wall. prepared by ethanol percolation and extraction and ethanol elutionon and 3,5,3',4'-tetrahydroxystilbene-4'-O-beta-D-glucopyranoside (PDG) can on one hand activate PI3K/AKT signal passage, influence the activation of antiapoptotic mechanism of myocardial cells in many ways and effectively inhibit the generation of myocardial cell apoptosis resulting from hypoxia induction and ischemia reperfusion myocardial cell apoptosis, and can on the other hand restate the balance of oxygen radicals and an oxyradical removing system through the effect of antioxidation, exerting further influence on myocardial cell apoptosis. Therefore, the extract of Rheum emodi Wall. has an obvious protective effect on myocardial ischemia of experiment animals resulting from multiple reasons and can be used for the preparation of medicines for treating or preventing IHD.
Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
PROBLEM TO BE SOLVED: To provide a method for taking and treating a pure edible swallow's nest, capable of forming primitive crystal of saliva of swallow into mud and powder, already sterilized and disinfected and capable of readily eating, readily carrying, storing for a long period and widely utilizing to health foods, cosmetics, etc., and obtain a food formulating the effective ingredient with royal jelly, etc., and a raw material for beauty cosmetic products capable of utilizing to external use, e.g. natural nourishing cosmetic or massage cream. SOLUTION: This method for producing extract of swallow's nest comprises permeating swallow's nest into mixed liquid of propolis with water and taking pure swallow's nest extract by grinding treatment using a grinder. This health food or natural nutrient cosmetic is obtained by forming the active ingredient in a form conveniently used, e.g. liquid, tablets, granules. Natural health and natural beauty effect are synergistically exhibited by formulating swallow's next with royal jelly in order to utilize both natural bacterial growth inhibiting effects and combine two intrinsic beauties with vigorous source.
Patients receive oral tamoxifen citrate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities.
Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
<P>PROBLEM TO BE SOLVED: To obtain a novel and safe agent or a cosmetic composition for inhibiting the activity of collagenase.  <P>SOLUTION: The agent or the cosmetic composition for inhibiting the activity of collagenase contains at least one extracted product of plant selected from the group consisting of Rubus palmatus Thunb. forma optophyllns Makino, Syzygium aromaticum (L) Marrill et Perry (Eugenia caryophyllata Thunb.), Eriobotrya japonica Lindl., Morus alba L., and Astragalus sinicus L. The agent possesses an inhibitory effect on the activity of collagenase and the cosmetic composition gives tension and gloss to the skin, and improves wrinkles and slacks of the skin, therefore the composition is effective for protecting aging of the skin, thus the agent can be applied to all the types of preparations (pharmaceuticals, quasi-drugs, cosmetics). Additionally, the agent can also be utilized to general foods and beverages.  <P>COPYRIGHT: (C)2003,JPO
Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. They will then be offered six sessions of the Broad-Minded Affective Coping (BMAC) Intervention. Sessions will take place weekly where possible and the intervention window will be eight weeks. A booster session will be offered in the 8 weeks following the end of therapy.
The invention relates to the field of medicines for treating nodules of breast, and particularly relates to a traditional Chinese medicine composition for treating nodules of breast and a preparation method thereof. The composition is specifically prepared from radix bupleuri, radix paeoniae alba, perilla stems, seaweed, kelp, ginger processed pinellia, pericarpium citri reticulatae, rhizoma sparganii, thunberg fritillary bulb, raw ginger, fructus aurantii, trogopterus dung, turtle shell angelica sinensis and curcuma zedoary in a specific proportion. The composition is handed down for generations, has good effects of promoting blood circulation to remove stasis, dredging unsmooth circulation of qi and blood, resolving stagnation and the like due to coordination and enhancement of raw materials, can be used for radically treating nodules of breast, takes effect after being taken for 2 days, enables masses to be eliminated after being taken for 12 weeks, has a cure rate of over 85 percent, and has the advantages of remarkable treatment effect, safety and no toxic or side effect. The preparation method comprises the steps of decocting and concentrating the raw materials, mixing with turtle shell powder to prepare granules and preparing capsules. The traditional Chinese medicine composition is convenient to take, can be well absorbed, is simple and feasible in preparation method, is not added with other medicinal auxiliaries, and is safe and reliable. Preparations prepared from the traditional Chinese medicine composition have a remarkable curative effect.
An implantable medical device is disclosed. A housing includes a hollow body forming a first electrode on an outer surface with end caps affixed to opposite ends, one end cap forming a second electrode. A microcontroller circuit is provided and includes a microcontroller operable under program instructions stored within a non-volatile memory device. An analog front end is interfaced to the electrodes to sense electrocardiographic signals. A transceiver circuit is operable to wirelessly communicate with an external data device. The program instructions define instructions to continuously sample the electrocardiographic signals into the non-volatile memory device and to offload the non-volatile memory device to the external data device. A receiving coil and a charging circuit are operable to charge an onboard power source for the microcontroller circuit.
The present invention can provide the following which is a transparent aqueous solution of a sufficient amount of ebselen and usable as an injection. A water-based preparation or aqueous solution comprising ebselen and cyclodextrin. An injection comprising the aqueous solution. An intravenous drip infusion comprising the aqueous solution. A process for producing an aqueous solution containing ebselen and cyclodextrin, which comprises dissolving ebselen in a water-miscible organic solvent while separately dissolving a cyclodextrin in a water solvent, mixing both the solutions, then drying the mixture, and mixing the resulting dried product with a water solvent. A dried preparation comprising ebselen and cyclodextrin. A process for producing a solution containing ebselen and cyclodextrin, which comprises dissolving ebselen in a water-miscible organic solvent while separately dissolving cyclodextrin in a water solvent, and mixing both the solutions.
CNS Depressants: Morphine should be used with great caution and in reduced dosage in patients who are concurrently receiving other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, other tranquilizers and alcohol because of the risk of respiratory depression, hypotension and profound sedation or coma. When such combined therapy is contemplated, the initial dose of one or both agents should be reduced by at least 50%.

Muscle Relaxants: morphine sulfate extended-release may enhance the neuromuscular blocking action of skeletal relaxants and produce an increased degree of respiratory depression.

Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as morphine sulfate extended-release. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of morphine sulfate extended-release c and/or may precipitate withdrawal symptoms in these patients.

Monoamine Oxidase Inhibitors (MAOIs): MAOIs have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma. Morphine sulfate extended-release should not be used in patients taking MAOIs or within 14 days of stopping such treatment.

Cimetidine: There is an isolated report of confusion and severe respiratory depression when a hemodialysis patient was concurrently administered morphine and cimetidine.

Diuretics: Morphine can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Morphine may also lead to acute retention of urine by causing spasm of the sphincter of the bladder, particularly in men with prostatism.
PURPOSE: The Systemic Immune-inflammatory Index (SII) and Geriatric Nutritional Risk Index (GNRI) have undergone comprehensive examination and validation in forecasting the outcomes of diverse medical conditions. Nevertheless, the correlation between the combined use of GNRI and SII metrics and hip fractures has yet to be elucidated. This study aimed to determine whether the amalgamation of SII and GNRI scores constitutes an independent prognostic factor for elderly patients with hip fractures.
METHODS: We conducted a retrospective analysis of elderly patients admitted to our facility with hip fractures, encompassing both femoral neck and intertrochanteric fractures. Demographic information, experimental parameters, and postoperative complications were systematically recorded. The Geriatric Nutritional Risk Index (GNRI) and Systemic Immunoinflammatory Index (SII) were meticulously computed. Receiver operating characteristic (ROC) curves were generated, and optimal cutoff values for each parameter were determined. Subsequently, a multivariate Cox regression analysis was employed to assess the predictive utility of the SII-GNRI score in relation to 1-year postoperative mortality among elderly patients with hip fractures.
RESULTS: In a study involving 597 patients, 90 of whom experienced mortality within 1 year, it was observed that the SII-GNRI score in the group of patients who passed away was significantly higher compared to the group that survived. Following a multifactorial adjustment, it was established that a high SII-GNRI score served as an independent predictor of 1-year all-cause mortality in older patients with hip fractures. In addition to the SII-GNRI score, factors such as length of hospital stay, CCI > 2, and blood transfusion were also identified as independent risk factors for survival. Notably, the incidence of postoperative complications in patients with high SII-GNRI scores was significantly greater than in patients with low scores.
CONCLUSION: The SII-GNRI score proves valuable in predicting the 1-year survival rate for elderly patients with hip fractures who have undergone surgery.
OBJECTIVES: In a longitudinal cohort of patients with HIV and chronic pain, we sought to (1) identify trajectories of opioid misuse and opioid use disorder (OUD) symptoms, and to (2) determine whether prescription opioid dose was associated with symptom trajectories.
METHODS: We leveraged an existing 12-month longitudinal observational study, Project PIMENTO, of persons living with HIV and chronic pain who received care at a hospital system in the Bronx, New York. A quota sampling strategy was used to ensure variability of prescribed opioid use in the recruited sample. Research interviews occurred quarterly and assessed opioid behaviors and criteria for OUD. To describe symptom trajectories, we conducted 2 separate longitudinal latent class analyses to group participants into (1) opioid misuse and (2) OUD trajectories. Finally, we used multinomial logistic regression models to examine the relationship between baseline prescription opioid dose and symptom trajectories.
RESULTS: Of 148 total participants, at baseline 63 (42.6%) had an active opioid prescription, 69 (46.6%) met the criteria for current opioid misuse, and 44 (29.7%) met the criteria for current OUD. We found 3 opioid misuse and 3 OUD symptom trajectories, none of which showed worsened symptoms over time. In addition, we found that higher prescription opioid dose at baseline was associated with a greater OUD symptom trajectory.
CONCLUSIONS: Opioid misuse and OUD were common but stable or decreasing over time. Although these results are reassuring, our findings also support prior studies that high-dose opioid therapy is associated with greater OUD symptoms.
Eukaryotic translation initiation factors (eIFs) are the primary targets for overcoming RNA virus resistance in plants. In a previous study, we mapped a BjeIF2Bβ from Brassica juncea representing a new class of plant virus resistance genes associated with resistance to Turnip mosaic virus (TuMV). However, the mechanism underlying eIF2Bβ-mediated virus resistance remains unclear. In this study, we discovered that the natural variation of BjeIF2Bβ in the allopolyploid B. juncea was inherited from one of its ancestors, B. rapa. By editing of eIF2Bβ, we were able to confer resistance to TuMV in B. juncea and in its sister species of B. napus. Additionally, we identified an N6-methyladenosine (m6A) demethylation factor, BjALKBH9B, for interaction with BjeIF2Bβ, where BjALKBH9B co-localized with both BjeIF2Bβ and TuMV. Furthermore, BjeIF2Bβ recruits BjALKBH9B to modify the m6A status of TuMV viral coat protein RNA, which lacks the ALKB homologue in its genomic RNA, thereby affecting viral infection. Our findings have applications for improving virus resistance in the Brassicaceae family through natural variation or genome editing of the eIF2Bβ. Moreover, we uncovered a non-canonical translational control of viral mRNA in the host plant.
PD-1 inhibitor combined with radiotherapy, whether PD-1 inhibitor was used alone or in combination with other drugs was determined by the investigator. According to the lesion sties, SBRT or hyperfractionated radiotherapy was used.
PURPOSE: To obtain a depilatory capable of removing hair in a wide range, maintaining effects for a relatively long period of time and causing no inflammation, derived from natural products, by formulating honey with sugar and citric acid. CONSTITUTION: A large amount of honey and sugar are mixed with a small amount of citric acid and stirred under a middle fire. The amount of honey is larger than that of sugar. The mixture is heated at altitude of one mile above sea level until the temperature reaches 275 deg.F. Otherwise, the mixture is heated for 1-2 hours at a temperature somewhat lower than a temperature at which the mixture is solidified. Then the mixture is cooled to room temperature for 5-10 minutes and injected into a container to give the objective substance. When the depilatory is solidified, it is placed on a stove, irradiated with microwave or several drops of warm water is dripped on the depilatory to soften and use the depilatory. The depilatory is stuck fast to skin to be applied and hair growing on the skin and the depilatory is peeled from the skin by fingers or pulled out to completely remove hair.